Want to join the conversation?
$ALXN 2Q15 Call: In Japan, ALXN received regulatory approval for Strensiq as a treatment for patients with HPP. The youngest HPP patients treated with Strensiq had an 84% overall survival. Working with Japanese healthcare authorities to make this breakthrough therapy available to patients as quickly as possible.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.